Purine metabolites and uric acid pool

The purine metabolites and uric acid pool encompass the biochemical intermediates and the final nitrogenous waste product resulting from the breakdown of purine nucleotides like adenine and guanine (StatPearls, 2023). In humans, the evolutionary loss of the uricase enzyme results in uric acid being the terminal product of purine degradation, necessitating efficient renal and gastrointestinal excretion to prevent accumulation (NIH, 2022). Dysregulation of this pool, typically manifesting as hyperuricemia, leads to the deposition of monosodium urate crystals in joints and soft tissues, triggering the inflammatory condition known as gout (Nature Reviews Rheumatology, 2020). Beyond gout, imbalances in this pool are associated with nephrolithiasis, chronic kidney disease, and cardiovascular pathologies (PubMed, 2021). Therapeutic strategies focus on modulating this pool by either inhibiting production via xanthine oxidase inhibitors or enhancing excretion through uricosuric agents that target renal transporters like URAT1 (Journal of Clinical Medicine, 2021). Additionally, recombinant uricase enzymes can be used to rapidly deplete the uric acid pool by converting it into the more soluble metabolite allantoin (FDA, 2022). Monitoring serum uric acid levels remains the gold standard for assessing the state of this metabolic pool and the efficacy of pharmacological interventions (StatPearls, 2023).

Other names

Purine metabolismUrate poolUric acid homeostasisPurine degradation pathway

Inhibition of uric acid production, enhancement of renal uric acid excretion, and enzymatic degradation of uric acid.